FOSUN INTL(00656) 中国银河·2024-12-29 03:36Investment Rating - The report assigns a "Buy" rating to Fosun International [2][21]. Core Views - Fosun International focuses on optimizing its core business and asset structure, which has led to improved valuation potential. The company has achieved steady revenue growth driven by its four main business segments: Health, Happiness, Wealth, and Intelligent Manufacturing [1][4][21]. - The company plans to reduce its interest-bearing debt to 60 billion RMB and gradually increase its dividend payout ratio, reflecting a commitment to shareholder value [4][21]. Summary by Sections Company Overview - Fosun International has developed into a global family consumption industry group over 30 years, with a diversified presence across more than 35 countries [8][29]. - The company operates in four main segments: Health, Happiness, Wealth, and Intelligent Manufacturing, with a strong emphasis on innovation [8][34]. Financial Performance - In the first half of 2024, Fosun International reported revenue of 97.838 billion RMB, a year-on-year increase of 0.8%, and an operating profit of 3.47 billion RMB, up 3.0% [1][21]. - The overseas revenue reached 45.87 billion RMB, accounting for 47% of total revenue, reflecting a 2 percentage point increase year-on-year [1]. Business Segments - Health Segment: Fosun Pharma is the core of the health segment, contributing significantly to revenue. The pharmaceutical business focuses on innovative drugs, with a notable increase in revenue from this area [15][40]. - Happiness Segment: This segment includes consumer brands and tourism, with stable performance driven by brands like Yuyuan and Club Med [19][42]. - Wealth Segment: The insurance business provides a stable funding source, with a successful turnaround in profitability [51][66]. - Intelligent Manufacturing Segment: This segment has shown significant growth, with a compound annual growth rate (CAGR) of 37.4% since its establishment [34][73]. Valuation and Future Outlook - The report forecasts net profits of 1.8 billion RMB, 2.8 billion RMB, and 3.6 billion RMB for 2024, 2025, and 2026, respectively, with corresponding price-to-earnings ratios of 21X, 14X, and 11X [21][22]. - The current market valuation is considered reasonable, with potential for further growth as the company strengthens its global and innovative strategies [21].